Team - The GeNose C19 Team of Universitas Gadjah Mada (UGM) succeeded in publishing GeNose C19 research data as a COVID-19 screening tool in two reputable international journals in August 2022.
The two journals are Artificial Intelligence in Medicine (AIIM) and Nature portfolio journal (npj) Digital Medicine, both of which are Q1 journals.
The inventor of GeNose C19, Kuwat Triyana, said that the GeNose C19 UGM team had published part of the GeNose C19 data research as part of the scientific responsibility for downstream research on the implementation of GeNose C19 as a COVID-19 screening tool.
"The two publications are the initial stages of the total data currently in the process of completing the manuscript writing, namely related to data from multicenter clinical trials and external tests involving multi-institutions," he said, quoted on the UGM website, Tuesday (30/8/2022).
1. GeNose research data published in two international journals
Kuwat explained that GeNose C19 research data was successfully published in Artificial intelligence in Medicine (AIIM), which is a Q1 journal with an impact factor of 7,011, entitled Hybrid learning method based on feature clustering and scoring for enhanced COVID-19 breath analysis by an electronic nose, published in May 2022 (Vol. 129(02233), pp. 1-13).
Meanwhile, in the Nature portfolio journal (npj) Digital Medicine , which is a Q1 journal with an impact factor of 15,357, with the title Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition, published in August 2022 (Vol. 5(1) 115), pp. 1-17).
"The acceptance of the publication of GeNose's research results shows that the concept of sensing infection with analysis of volatile organic compounds (VOC) breath based on big data, and artificial intelligence (AI) can be accepted in clinical applications," said Kuwat.
2. The use of AI and information technology is a revolution
With the acceptance of this concept, Kuwat said, the use of AI and information technology has become a revolution in disease management, both infectious and non-infectious diseases. Data collected from patients with certain standardized methods can be a source of new biomarkers that are valid, reproducible and affordable.
“It only takes continuous testing and updates from the database, as well as AI algorithms to continuously improve diagnostic performance. The hybrid -based learning process is discussed in full in the first manuscript, while the process of testing the learning results by means of a multicenter diagnostic test as well as the results of external validation will be published in the next reputable international journal," he said.
3. Publication shows recognition from the world
Meanwhile, UGM Chancellor, Ova Emilia, said that the publication of GeNose C19 in these two international reputable journals shows recognition from the world that the volatile method of infection identification is acceptable. This shows a paradigm shift in the process of identifying an infection.
"In the past, it was the identification of the animal, now, judging from the symptoms, it can be identified with the concept of a lot of data, so that patterns are collected that lead to certain diseases," he said.